Prostate Cancer Foundation

donate ribbon

Donate Now    FAQs   Contact Us   Español   twitter   facebook


Research News

Xofigo Results Published in New England Journal of Medicine – Explanatory Video Accompanies Publication

July 24, 2013 -- The New England Journal of Medicine has just published results from the clinical trial known as ALSYMPCA—a multinational, double-blind, randomized, placebo-controlled Phase III evaluation of the drug marketed as Xofigo—showing improved survival, better quality of life for men who received the drug.

The Prostate Cancer Foundation has repeatedly reported on this drug’s development and movement to market, the approval by the Food and Drug Administration this spring, and the findings show the drug not only extends survival time for men with metastatic prostate cancer that has spread to bone, but also markedly improves their quality of life.

The NEJM put out this educational video on the drug and also a blog by physician-in-training (at Harvard Medical School), Rena Xu that summarizes the findings of the study.

Additionally Prostate Cancer Foundation Young Investigator Neha Vapiwala, MD co-wrote an editorial the accompanied the study. Being asked to opine on such an important study is a great honor and we congratulate not only Dr. Vapiwala, but all the dedicated researchers who worked so hard to bring this drug to market and the seed funding provided by PCF donors that paved the way for the eventual marketing of Xofigo.

Back to Research and Therapeutics

Back to All Research News



Print | Bookmark and Share

2000 Programs Worldwide

Progress Reports

prostate cancer guides and books

prostate cancer clinical trials

patient support

athletes for a cure